AMEX · ARMP

Armata Pharmaceuticals, Inc.

$4.66 -$0.56 (-10.73%) 1D Market open

Key Metrics

$191.63M
Market cap
P/E · TTM
Revenue · TTM
−$282.61M
Net income
EPS · TTM $-4.75
Dividend yield
Free cash flow −$24.47M
Beta · 1Y 0.49
EBITDA · TTM −$172.78M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    The stock moved +19.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 17
  • Jul 16
    From its Apr 21 high, the share price fell 75%.

    Peak close $14.80 on Apr 21; trough close $3.76 on Jul 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -75%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 24
    The stock moved +24.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$191.63M
Enterprise value
Shares outstanding36.7M
52-wk range$2.35 – $16.34
Avg volume · 20D53.5K
Net cash
Book value / share$-5.24
IndustryBiological Products, (No Diagnostic Substances)
ExchangeAMEX
About Armata Pharmaceuticals, Inc.
IPO dateMay 27, 1994
Employees61

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based tec…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 157.2% · —

Financial Health

Current ratio0.64
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$3.28M

Cash Flow · TTM

Operating CF −$23.97M
Capex −$506.00K
Free cash flow −$24.47M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings